Abstract
Objective
The purpose of this study is to assess the relationship between chemotherapy toxicity and frailty as determined using the Edmonton Frail Scale (EFS).
Methods
Older adults (≥ 65 years old) newly diagnosed with cancer were evaluated for frailty with EFS prior to chemotherapy. Participants evaluated on 17 points were grouped as “No Frailty” (0–4), “Apparently Vulnerable” (5–6), “Mild Frailty” (7–8), “Moderate Frailty” (9–10), and “Severe Frailty” (11 or more). Before the second and third chemotherapy cycles, patients were reassessed for toxicity.
Results
Of the 44 participants, 12 (27.4%) were rated as “frail” (EFS score ≥ 7). The median Charlson Age-Comorbidity Index score was 3 (IQR: 1), and the median EFS score was 5 (IQR: 3). There was no significant difference between the “frail” and “robust” groups in terms of the toxicity. There was no correlation between age, gender, chemotherapy intent, chemotherapy dosing, ECOG performance score, or other parameters with grade 3 or higher toxicity development.
Conclusion
The Edmonton Frail Scale is not successful in predicting the toxicity risk of chemotherapy. However, it may be used as a tool to determine the need for comprehensive geriatric assessment and it may lead to increased alertness to adverse events during treatment of frail patients.
Similar content being viewed by others
Data availability
The datasets generated during and/or analyzed during the current study are not publicly available due to ethical concerns but are available from the corresponding author on reasonable request.
Code availability
N/A.
References
Howlader N, Noone A, Krapcho M, Garshell J, Neyman N, Altekruse S, et al. SEER cancer statistics review, 1975–2010.[Based on the November 2012 SEER data submission, posted to the SEER web site, April 2013.]. Bethesda, MD: National Cancer Institute. 2013;9.
Muss HB, Berry DA, Cirrincione C, Budman DR, Henderson IC, Citron ML et al (2007) Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience. J Clin Oncol 25(24):3699–3704
Goldberg RM, Tabah-Fisch I, Bleiberg H, de Gramont A, Tournigand C, Andre T et al (2006) Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 24(25):4085–4091. https://doi.org/10.1200/JCO.2006.06.9039
Figer A, Perez-Staub N, Carola E, Tournigand C, Lledo G, Flesch M et al (2007) FOLFOX in patients aged between 76 and 80 years with metastatic colorectal cancer: an exploratory cohort of the OPTIMOX1 study. Cancer 110(12):2666–2671. https://doi.org/10.1002/cncr.23091
Handforth C, Clegg A, Young C, Simpkins S, Seymour MT, Selby PJ et al (2015) The prevalence and outcomes of frailty in older cancer patients: a systematic review. Ann Oncol 26(6):1091–1101. https://doi.org/10.1093/annonc/mdu540
Kalsi T, Babic-Illman G, Fields P, Hughes S, Maisey N, Ross P et al (2014) The impact of low-grade toxicity in older people with cancer undergoing chemotherapy. Br J Cancer 111(12):2224–2228
Wildiers H, Heeren P, Puts M, Topinkova E, Janssen-Heijnen ML, Extermann M et al (2014) International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol 32(24):2595–2603
Morley JE, Vellas B, van Kan GA, Anker SD, Bauer JM, Bernabei R et al (2013) Frailty consensus: a call to action. J Am Med Dir Assoc 14(6):392–397. https://doi.org/10.1016/j.jamda.2013.03.022
Luciani A, Biganzoli L, Colloca G, Falci C, Castagneto B, Floriani I et al (2015) Estimating the risk of chemotherapy toxicity in older patients with cancer: the role of the Vulnerable Elders Survey-13 (VES-13). J Geriatr Oncol 6(4):272–279. https://doi.org/10.1016/j.jgo.2015.02.005
Alibhai SM, Aziz S, Manokumar T, Timilshina N, Breunis H (2017) A comparison of the CARG tool, the VES-13, and oncologist judgment in predicting grade 3+ toxicities in men undergoing chemotherapy for metastatic prostate cancer. J Geriatr Oncol 8(1):31–36. https://doi.org/10.1016/j.jgo.2016.09.005
Baitar A, Van Fraeyenhove F, Vandebroek A, De Droogh E, Galdermans D, Mebis J et al (2014) Geriatric screening results and the association with severe treatment toxicity after the first cycle of (radio) chemotherapy. Journal of geriatric oncology 5(2):179–184
Rolfson DB, Majumdar SR, Tsuyuki RT, Tahir A, Rockwood K (2006) Validity and reliability of the Edmonton Frail Scale. Age Ageing 35(5):526–529
Program NCICTE. Common terminology criteria for adverse events: (CTCAE). Cancer Therapy Evaluation Program; 2010.
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, Mcfadden ET et al (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5(6):649–656
Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373–383
Charlson M, Szatrowski TP, Peterson J, Gold J (1994) Validation of a combined comorbidity index. J Clin Epidemiol 47(11):1245–1251
Radovanovic D, Seifert B, Urban P, Eberli FR, Rickli H, Bertel O, et al. Validity of Charlson Comorbidity Index in patients hospitalised with acute coronary syndrome. Insights from the nationwide AMIS Plus registry 2002–2012. Heart. 2013:heartjnl-2013–304588.
Perna S, Francis MD, Bologna C, Moncaglieri F, Riva A, Morazzoni P et al (2017) Performance of Edmonton Frail Scale on frailty assessment: its association with multi-dimensional geriatric conditions assessed with specific screening tools. BMC Geriatr 17(1):2. https://doi.org/10.1186/s12877-016-0382-3
Aygör HE, Fadıloğlu Ç, Aykar FŞ, Akçiçek F (2013) Testing the reliability and validity of the “Edmonton Frail Scale” in Turkish population. European Geriatric Medicine 4:S76
Lyman GH, Morrison VA, Dale DC, Crawford J, Delgado DJ, Fridman M (2003) Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin’s lymphoma receiving CHOP chemotherapy. Leuk Lymphoma 44(12):2069–2076
Janssen-Heijnen ML, Extermann M, Boler IE (2011) Can first cycle CBCs predict older patients at very low risk of neutropenia during further chemotherapy? Crit Rev Oncol Hematol 79(1):43–50. https://doi.org/10.1016/j.critrevonc.2010.07.001
Shayne M, Culakova E, Poniewierski MS, Wolff D, Dale DC, Crawford J et al (2007) Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy. Cancer 110(7):1611–1620. https://doi.org/10.1002/cncr.22939
Freyer G, Geay JF, Touzet S, Provencal J, Weber B, Jacquin JP et al (2005) Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: a GINECO study. Ann Oncol 16(11):1795–1800. https://doi.org/10.1093/annonc/mdi368
Puts MT, Monette J, Girre V, Pepe C, Monette M, Assouline S et al (2011) Are frailty markers useful for predicting treatment toxicity and mortality in older newly diagnosed cancer patients? Results from a prospective pilot study. Crit Rev Oncol Hematol 78(2):138–149
Clough-Gorr KM, Stuck AE, Thwin SS, Silliman RA (2010) Older breast cancer survivors: geriatric assessment domains are associated with poor tolerance of treatment adverse effects and predict mortality over 7 years of follow-up. J Clin Oncol 28(3):380–386. https://doi.org/10.1200/JCO.2009.23.5440
Biesma B, Wymenga AN, Vincent A, Dalesio O, Smit HJ, Stigt JA et al (2011) Quality of life, geriatric assessment and survival in elderly patients with non-small-cell lung cancer treated with carboplatin-gemcitabine or carboplatin-paclitaxel: NVALT-3 a phase III study. Ann Oncol 22(7):1520–1527. https://doi.org/10.1093/annonc/mdq637
Pilnik N, Ibero MM, Carri D, Mareca O (2010) Influence of some clinical parameters in the tolerance to treatment in elderly patients with advanced lung cancer. J Clin Oncol 28(15_suppl):e19600-e
Meyers BM, Al-Shamsi HO, Rask S, Yelamanchili R, Phillips CM, Papaioannou A et al (2017) Utility of the Edmonton Frail Scale in identifying frail elderly patients during treatment of colorectal cancer. J Gastrointest Oncol 8(1):32–8. https://doi.org/10.21037/jgo.2016.11.12
Hurria A, Togawa K, Mohile SG, Owusu C, Klepin HD, Gross CP et al (2011) Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol 29(25):3457–3465
Hurria A, Mohile S, Gajra A, Klepin H, Muss H, Chapman A et al (2016) Validation of a prediction tool for chemotherapy toxicity in older adults with cancer. J Clin Oncol 34(20):2366–2371. https://doi.org/10.1200/JCO.2015.65.4327
Extermann M, Boler I, Reich RR, Lyman GH, Brown RH, DeFelice J et al (2012) Predicting the risk of chemotherapy toxicity in older patients: the chemotherapy risk assessment scale for high-age patients (CRASH) score. Cancer 118(13):3377–3386
Author information
Authors and Affiliations
Contributions
All authors contributed to the design and implementation of the research, to the analysis of the results, and to the writing of the manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Ethics approval
This study received the approval of Hacettepe University Non-interventional Clinical Research Ethics Committee.
Consent to participate
Informed consent was obtained from all individual participants included in the study.
Conflict of interest
The authors declare no competing interests.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Akbıyık, I., Yüce, D., Kars, A. et al. Association of frailty with chemotherapy toxicity in chemotherapy-naive older patients with cancer. Support Care Cancer 30, 9975–9981 (2022). https://doi.org/10.1007/s00520-022-07448-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00520-022-07448-x